AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The companys pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors for renal cell carcinoma and other cancers; Ficlatuzumab, an anti-hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer, including chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincents Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.